Delivra Health Brands Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Delivra Health Brands hat ein Gesamteigenkapital von CA$3.6M und eine Gesamtverschuldung von CA$2.0M, was einen Verschuldungsgrad von 55.4% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen CA$9.3M bzw. CA$5.8M.

Wichtige Informationen

55.4%

Verhältnis von Schulden zu Eigenkapital

CA$1.97m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	CA$3.40m
Eigenkapital	CA$3.56m
Gesamtverbindlichkeiten	CA$5.76m
Gesamtvermögen	CA$9.31m

Jüngste Berichte zur Finanzlage

Health Check: How Prudently Does Harvest One Cannabis (CVE:HVT) Use Debt?

May 29

Recent updates

Health Check: How Prudently Does Harvest One Cannabis (CVE:HVT) Use Debt?

May 29

Did The Underlying Business Drive Harvest One Cannabis' (CVE:HVT) Lovely 345% Share Price Gain?

Feb 11

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: DHBDie kurzfristigen Aktiva des Unternehmens (CA$7.7M) übersteigen seine kurzfristigen Passiva (CA$4.0M).

Langfristige Verbindlichkeiten: DHBDie kurzfristigen Vermögenswerte des Unternehmens (CA$7.7M) übersteigen seine langfristigen Verbindlichkeiten (CA$1.7M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: DHB über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: DHBDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 0% auf 55.4% gestiegen.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: DHB auf der Grundlage seines derzeitigen freier Cashflows über eine ausreichende Liquiditätsreserve für mehr als 3 Jahre verfügt.

Vorhersage Cash Runway: Unzureichende Daten, um festzustellen, ob DHB über genügend Cash Runway verfügt, wenn sein freier Cashflow auf der Grundlage historischer Raten weiter wächst oder schrumpft.

Delivra Health Brands Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Health Check: How Prudently Does Harvest One Cannabis (CVE:HVT) Use Debt?

Recent updates

New minor risk - Profitability

Third quarter 2024 earnings released: CA$0.001 loss per share (vs CA$0.003 loss in 3Q 2023)

Second quarter 2024 earnings released: CA$0.002 loss per share (vs CA$0.004 profit in 2Q 2023)

Delivra Health Brands Inc., Annual General Meeting, Apr 29, 2024

New minor risk - Shareholder dilution

Delivra Health Brands Inc. announced that it has received CAD 0.9 million in funding

Delivra Health Brands Inc. announced that it expects to receive CAD 0.9 million in funding

Delivra Health Brands Inc. announced that it expects to receive CAD 0.9 million in funding

First quarter 2024 earnings released: EPS: CA$0.001 (vs CA$0.002 loss in 1Q 2023)

Insufficient new directors

Full year 2023 earnings released: CA$0.001 loss per share (vs CA$0.028 loss in FY 2022)

Delivra Health Brands Inc. to Report Fiscal Year 2023 Results on Oct 18, 2023

Third quarter 2023 earnings released: CA$0.003 loss per share (vs CA$0.007 loss in 3Q 2022)

Delivra Health Brands Inc. to Report Q3, 2023 Results on May 23, 2023

Second quarter 2023 earnings released: EPS: CA$0.004 (vs CA$0.006 loss in 2Q 2022)

First quarter 2023 earnings released: CA$0.002 loss per share (vs CA$0.006 loss in 1Q 2022)

Full year 2022 earnings released: CA$0.028 loss per share (vs CA$0.09 loss in FY 2021)

Delivra Health Brands Inc. to Report Fiscal Year 2022 Results on Oct 28, 2022

Third quarter 2022 earnings released: CA$0.007 loss per share (vs CA$0.005 loss in 3Q 2021)

Harvest One Cannabis Inc. Provides Earnings Guidance for the Fourth Quarter of 2022

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Harvest One Continues to Expand its Licensed LivRelief InfusedTM Product Line with the Listing of Extra Strength Transdermal CBD Cream at the OCS

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Full year 2021 earnings released: CA$0.13 loss per share (vs CA$0.28 loss in FY 2020)

Health Check: How Prudently Does Harvest One Cannabis (CVE:HVT) Use Debt?

Third quarter 2021 earnings released: CA$0.005 loss per share (vs CA$0.17 loss in 3Q 2020)

Harvest One Cannabis Inc. Announces the Launch of Its New LivRelief

Harvest One Cannabis Inc. has completed a Composite Units Offering in the amount of CAD 4.99999 million.

Cann Group Limited (ASX:CAN) completed the acquisition of Satipharm Ltd, Satipharm AG and Phytotech Therapeutics Ltd from Harvest One Cannabis Inc. (TSXV:HVT)

Second quarter 2021 earnings released

Cann Group Limited (ASX:CAN) entered into a definitive sale agreement to acquire Phytotech Therapeutics Ltd from Harvest One Cannabis Inc. (TSXV:HVT).

Cann Group Limited (ASX:CAN) signed a share sale agreement to acquire Satipharm Ltd from Harvest One Cannabis Inc. (TSXV:HVT) for CAD 4 million.

Harvest One Continues International Expansion with Asian Distribution Agreement for Dream Water Products

Did The Underlying Business Drive Harvest One Cannabis' (CVE:HVT) Lovely 345% Share Price Gain?

New 90-day high: CA$0.24

Harvest One Cannabis Inc. Expands Distribution of Dream Water Products in the United States and Internationally

Harvest One Cannabis Inc. Announces Executive Changes

Full year earnings released - CA$0.29 loss per share

An unknown buyer acquired a majority stake in Greenbelt Greenhouse Ltd from Harvest One Cannabis Inc. (TSXV:HVT) for approximately CAD 2.9 million.

Harvest One Cannabis Inc. Announces Management Changes

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Liquiditätsreserve-Analyse

Entdecken Sie finanziell stabile Unternehmen